Search NLS News

The company has announced the receipt of a funding award from the UK Vaccine Network program. This research program is funded by the Department of Health and Social Care as part of the UK Vaccine Network (UKVN), a UK Aid programme to develop vaccines for diseases with epidemic potential in low and middle-income countries (LMICs). […]

The company has announced topline results from the phase IIa trial of its lead product FG001 in guiding surgery in patients with head & neck cancer, confirming positive efficacy and safety. “These encouraging first clinical results, showing that FG001 was able to light up cancer in all head & neck cancer patients in the trial, […]

The company has presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference. Poster 1 demonstrates the safety profile of TILT-123 monotherapy and showcases promising efficacy results, including anti-tumor activity and the induction of […]

The speed at which artificial intelligence (AI) is becoming part of everyday life has taken much of the world by surprise, but perhaps less so in the Nordic countries where much of the infrastructure already exists to accommodate the new technology.

The company has successfully secured financing in an oversubscribed funding round. “This funding will propel our efforts in establishing key partnerships and driving SiPore technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management,” says Sana Alajmovic, Sigrid’s Co-Founder […]

SynAct Pharma has announced evaluation of the 4-week RESOLVE Phase 2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate. During the evaluation of the unblinded study data SynAct Pharma identified multiple issues that need further investigation before any conclusion on the outcome of the study can be […]

The company has announced the appointment of Professor Jeremy Shefner, MD, PhD at the Gregory W. Fulton ALS & Neuromuscular Disease Center, the Department of Neurology at Barrow Neurological Institute in Phoenix, Arizona, USA as the third member of its newly-formed Scientific Advisory Board (SAB). “We are thrilled to welcome Dr. Shefner to join our […]

AstraZeneca has announced a collaboration and investment agreement with the French clinical-stage biotechnology company Cellectis to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis gene editing technologies and manufacturing capabilities, to design […]

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

The board of directors of Cantargia has resolved to carry out a directed new issue of 16,698,789 shares at a subscription price of SEK 3.55 per share. The Directed Share Issue will provide Cantargia with approximately SEK 59.3 million before deduction of transaction costs. Investors in the Directed Share Issue represent a variety of Swedish […]